RUA Rua Life Sciences Plc

TIDMRUA

RNS Number : 3631X

RUA Life Sciences PLC

20 December 2023

20 December 2023

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Heart Valve Leaflet Material - Testing Update

RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon(TM)), today provides an update on recent developments of the RUA leaflet composite.

The objective for RUA Structural Heart during 2023 was to evaluate heart valve leaflet material and compare the performance of 100% polymeric valves with the novel composite developed by the Group. The computational modelling of the composite material at the design stage suggested that its mechanical properties would be ideal for heart valve leaflets.

Testing undertaken by RUA has demonstrated:

   --      Flex fatigue stability over 400m cycles 
   --      Durability as a heart valve leaflet over 200m cycles 
   --      Remarkable tensile strength properties exceeding both base fabric and polymer 
   --      Similar tensile strength in multiple directions 
   --      Highly flexible allowing improved valve efficiency. 
   --      Narrow crimping profile allowing TAVR benefits 

-- Retention of ElastEon blood contacting properties such as calcification and thrombogenicity.

   --      Material very stable with no delamination during testing and high tear resistance. 

Patent protection for the material has now been sought and coupled with the testing results achieved RUA is now seeking to commercialise the RUA composite material as an alternative to animal tissue used in the manufacture of heart valves. Engagement with the industry has been positive and, as previously announced, a major heart valve company has approached the Company to undertake its own tests and has now entered into a material testing agreement (MTA) in order to do so.

While there can be no certainty that the parties will progress to an agreement, an MTA is the preliminary step to further collaboration.

Bill Brown, Chairman of RUA Life Sciences, stated : "Combining RUA's expertise in implantable textile materials with the clinically proven properties of ElastEon has created a novel material that appears to meet the key properties required of heart valve leaflets and it is pleasing that the business is now transitioning from a R&D phase into early stages of commercialisation."

For further information contact:

 
 RUA Life Sciences 
  Bill Brown, Chairman                       Tel: +44 (0)1294 
  Caroline Stretton, Group Managing          317073 
  Director                                   Tel: +44 (0)1294 
                                             317073 
 Cavendish Capital Markets Limited         Tel: +44 (0)20 7220 
  (Nominated Adviser and Broker)            0500 
  Giles Balleny/Dan Hodkinson (Corporate 
  Finance) 
  Charlie Combe (Broking) 
  Michael Johnson (Sales) 
 

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-Eon (TM) , the world's leading long-term implantable polyurethane. Whether it is licensing Elast-Eon (TM) , manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 
 RUA Contract        End-to-end contract developer and manufacturer 
  Manufacture:        of medical devices and implantable fabric 
                      specialist. 
 RUA Biomaterials:   Licensor of Elast-Eon (TM) polymers to 
                      the medical device industry. 
 RUA Vascular:       Commercialisation of open surgical vascular 
                      grafts and patches 
 RUA Structural      Development of polymeric leaflet systems 
  Heart:              for heart valves. 
 

100% polymeric valves rely in part on the leaflet design to reduce stress and operate within the performance window of the polymer meaning that polymer would not work in all designs. The composite material retains the blood contacting properties of Elast-Eon but is significantly stronger. This creates the opportunity for RUA Structural Heart to become a supplier of heart valve leaflets to other companies to incorporate in current designs.

Bill Brown, Chairman of the Company, commented: "RUA has a portfolio of four businesses, all of which have made good progress during the period. The mature businesses are growing revenue and generating attractive net margins and the development business segments of Vascular and Structural Heart have made good regulatory and technological progress respectively on relatively low levels of investment."

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCNKCBPABDDCBD

(END) Dow Jones Newswires

December 20, 2023 02:00 ET (07:00 GMT)

Rua Life Sciences (LSE:RUA)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Rua Life Sciences (LSE:RUA)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024